Monster Hunter is back, arriving with a whole suite of changes and franchise firsts that set Monster Hunter Wilds apart from its predecessors - making for possibly the most accessible, crowd ...

When is the Monster Hunter Wilds release date? Following Monster Hunter’s migration onto PC in recent years, we’re sharpening our blades in preparation for the next installment of Capcom’s ...

At 10.30am on a chilly Saturday the queue outside Manze’s pie-and-mash shop on Deptford High Street stretches 50 metres down the street. The restaurant has been a fixture of the south-east ...

Looking for a complete list of Monster Hunter Wilds monsters? The best way for any hunter to prepare for a trip to the Forbidden Lands is to get familiar with all the monsters that call it home.

Among patients with baseline and week 96 biopsies, 39 percent of participants treated with 50mg efruxifermin showed cirrhosis reversal with no worsening of MASH compared to 15 percent from placebo ...

Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales ...

Opens in a new tab or window In patients with severe metabolic dysfunction-associated steatohepatitis (MASH), the investigational drug efruxifermin significantly improved fibrosis without ...

Capcom’s Monster Hunter series is home to some of the most imaginative and intimidating monsters in video games. From majestic Flying Wyverns to climate-changing Elder Dragons, this series has ...

With Monster Hunter Wilds releasing in just over a month, it's worth studying the confirmed monsters we'll be hunting across the Forbidden Lands. Preparation is, after all, half of the hunter's ...

But one risk you may not be as familiar with is metabolic dysfunction–associated steatohepatitis (MASH). MASH is a type of liver inflammation and damage caused by a buildup of fat in the liver.

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...